PlainPharmaWatch

CMS Open Payments · Tool

ImpediMed, Inc. vs FEMSelect Inc.

Side-by-side comparison of CMS Open Payments data for Program Year 2024. Select different companies below to start a new comparison.

A larger reported total is not "better" or "worse", it is a neutral fact about disclosure volume; a reported payment documents a financial relationship, not evidence of wrongdoing.

Compare Different Companies

vs

Relationship comparison

Which recorded payment profile is more concentrated?

ImpediMed, Inc. has the more concentrated recorded General Payments recipient profile in Program Year 2024: its recipient-distribution HHI is 2,895, versus 2,552 for the other company. Its single largest recorded recipient represents 42.9% of that company's General Payments recipient total.

HHI summarizes how payments are distributed across recorded recipients: higher means a less evenly distributed recipient pattern. This is a description of CMS-reported General Payments only, not a finding about conduct, prescribing, quality, or wrongdoing. Read it with the recipient count and underlying records below.

ImpediMed, Inc.
HHI 2,895 · top recipient 42.9%
Ranked #581 of 1,838 companies by HHI
FEMSelect Inc.
HHI 2,552 · top recipient 44.9%
Ranked #638 of 1,838 companies by HHI

Payment Overview

Company A

ImpediMed, Inc.

Total Payments
$128.1K
% of Industry
0.0%
Transactions
97
Avg per Transaction
$1.3K
Recipients
97
Avg per Recipient
$1.3K
Payment Types
4
Top Payment Type
Consulting Fee
Company B

FEMSelect Inc.

Total Payments
$126.2K
% of Industry
0.0%
Transactions
195
Avg per Transaction
$647.38
Recipients
193
Avg per Recipient
$654.09
Payment Types
2
Top Payment Type
Consulting Fee

Highlighted values indicate the higher figure for each metric.

Total payments compared

ImpediMed, Inc. vs FEMSelect Inc. - total reported payments in CMS Open Payments PY2024

ImpediMed, Inc.$128.1KFEMSelect Inc.$126.2K

General Payment Types Breakdown

Category shares use each company's General Payments total, not the all-tracks (General + Research + Ownership) hero figure.

ImpediMed, Inc.

Consulting Fee $113.5K

88.6%

Honoraria $11.0K

8.6%

Food and Beverage $2.4K

1.9%

Compensation for Services Other Than Consulting $1.3K

1.0%

FEMSelect Inc.

Consulting Fee $54.8K

84.0%

Food and Beverage $10.4K

16.0%

Top 5 General-Payment Recipients

This list uses CMS detailed General Payments records only; it excludes research and ownership/investment records, so it does not equal the all-category totals above. A reported payment documents a financial relationship, not evidence of wrongdoing; a higher total reflects reporting volume, not conduct. Verify directly at openpaymentsdata.cms.gov.

ImpediMed, Inc.

  1. 1

    Chirag Shah

    $55,000.00 · 11 txns

  2. 2

    Walton Taylor

    $38,680.35 · 26 txns

  3. 3

    Allison DiPasquale

    $10,399.51 · 10 txns

  4. 4

    FRANK VICINI

    $10,000.00 · 2 txns

  5. 5

    Namita Chittoria

    $3,000.00 · 2 txns

FEMSelect Inc.

  1. 1

    VINCENT LUCENTE

    $29,285.24 · 12 txns

  2. 2

    GRACE BIGGS

    $13,362.69 · 8 txns

  3. 3

    SANDY NOSSEIR

    $4,746.19 · 4 txns

  4. 4

    ANTHONY GADDI

    $3,154.34 · 4 txns

  5. 5

    DANIEL JAFFEE

    $2,765.19 · 3 txns

Summary Comparison

Metric ImpediMed, Inc. FEMSelect Inc.
Total Payments $128.1K $126.2K
% of Industry Total 0.0% 0.0%
Transaction Count 97 195
Avg per Transaction $1.3K $647.38
Recipient Count 97 193
Avg per Recipient $1.3K $654.09
Payment Type Count 4 2
Top Payment Type Consulting Fee Consulting Fee

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. All companies in the CMS Open Payments company corpus are available in the selector. Browse all companies →

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.